DE2201513A1 - Neue Modifikation natuerlicher doppelstrangiger Ribonucleinsaeuren mit antiviraler Aktivitaet und verminderter akuter toxischer Wirkung,Verfahren zu ihrer Herstellung sowie eine solche Modifikation enthaltende Arzneipraeparate - Google Patents
Neue Modifikation natuerlicher doppelstrangiger Ribonucleinsaeuren mit antiviraler Aktivitaet und verminderter akuter toxischer Wirkung,Verfahren zu ihrer Herstellung sowie eine solche Modifikation enthaltende ArzneipraeparateInfo
- Publication number
- DE2201513A1 DE2201513A1 DE19722201513 DE2201513A DE2201513A1 DE 2201513 A1 DE2201513 A1 DE 2201513A1 DE 19722201513 DE19722201513 DE 19722201513 DE 2201513 A DE2201513 A DE 2201513A DE 2201513 A1 DE2201513 A1 DE 2201513A1
- Authority
- DE
- Germany
- Prior art keywords
- int
- double
- value
- solution
- modification
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims description 93
- 229920002477 rna polymer Polymers 0.000 title claims description 45
- 238000012986 modification Methods 0.000 title claims description 32
- 230000004048 modification Effects 0.000 title claims description 32
- 230000000840 anti-viral effect Effects 0.000 title claims description 12
- 238000000034 method Methods 0.000 title claims description 9
- 230000002829 reductive effect Effects 0.000 title description 6
- 230000001154 acute effect Effects 0.000 title description 4
- 231100000331 toxic Toxicity 0.000 title description 4
- 230000002588 toxic effect Effects 0.000 title description 4
- 238000004519 manufacturing process Methods 0.000 title description 2
- 230000008569 process Effects 0.000 title description 2
- 239000000243 solution Substances 0.000 claims description 92
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 87
- 239000011780 sodium chloride Substances 0.000 claims description 43
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 29
- 238000000926 separation method Methods 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 18
- 238000006460 hydrolysis reaction Methods 0.000 claims description 17
- 241000699670 Mus sp. Species 0.000 claims description 16
- 230000007062 hydrolysis Effects 0.000 claims description 16
- 241000710188 Encephalomyocarditis virus Species 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 230000002427 irreversible effect Effects 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 7
- 238000006731 degradation reaction Methods 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 239000002585 base Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003792 electrolyte Substances 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000008151 electrolyte solution Substances 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 52
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 35
- 238000012360 testing method Methods 0.000 description 22
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 15
- 238000010521 absorption reaction Methods 0.000 description 14
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 230000001681 protective effect Effects 0.000 description 10
- 229910000029 sodium carbonate Inorganic materials 0.000 description 10
- 239000000463 material Substances 0.000 description 9
- 231100000419 toxicity Toxicity 0.000 description 9
- 230000001988 toxicity Effects 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000000605 extraction Methods 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 208000015181 infectious disease Diseases 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000002211 ultraviolet spectrum Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000012085 test solution Substances 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- -1 amine salts Chemical class 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000001502 gel electrophoresis Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000002799 interferon inducing agent Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical group OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000228150 Penicillium chrysogenum Species 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- 229940038773 trisodium citrate Drugs 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- HFGHRUCCKVYFKL-UHFFFAOYSA-N 4-ethoxy-2-piperazin-1-yl-7-pyridin-4-yl-5h-pyrimido[5,4-b]indole Chemical compound C1=C2NC=3C(OCC)=NC(N4CCNCC4)=NC=3C2=CC=C1C1=CC=NC=C1 HFGHRUCCKVYFKL-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000702662 Cypovirus Species 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000941423 Grom virus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004852 Lung Injury Diseases 0.000 description 1
- 241001480512 Mammalian orthoreovirus 3 Species 0.000 description 1
- 229910001252 Pd alloy Inorganic materials 0.000 description 1
- 241000228145 Penicillium brevicompactum Species 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001136494 Talaromyces funiculosus Species 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 231100000515 lung injury Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Chemical class 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 231100000916 relative toxicity Toxicity 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000007740 vapor deposition Methods 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB194071A GB1356263A (en) | 1971-01-14 | 1971-01-14 | Modified double-stranded rna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2201513A1 true DE2201513A1 (de) | 1972-07-27 |
Family
ID=9730714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19722201513 Pending DE2201513A1 (de) | 1971-01-14 | 1972-01-13 | Neue Modifikation natuerlicher doppelstrangiger Ribonucleinsaeuren mit antiviraler Aktivitaet und verminderter akuter toxischer Wirkung,Verfahren zu ihrer Herstellung sowie eine solche Modifikation enthaltende Arzneipraeparate |
Country Status (13)
| Country | Link |
|---|---|
| AT (1) | AT340604B (enExample) |
| AU (1) | AU3796472A (enExample) |
| BE (1) | BE778102A (enExample) |
| CA (1) | CA966830A (enExample) |
| CH (1) | CH568760A5 (enExample) |
| DE (1) | DE2201513A1 (enExample) |
| DK (1) | DK129709B (enExample) |
| FR (1) | FR2121772B1 (enExample) |
| GB (1) | GB1356263A (enExample) |
| IE (1) | IE35980B1 (enExample) |
| NL (1) | NL7200481A (enExample) |
| SE (1) | SE386450B (enExample) |
| ZA (1) | ZA72169B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2353293A1 (fr) * | 1976-06-03 | 1977-12-30 | Beljanski Mirko | Polyribonucleotides ayant une activite dans la genese des leucocytes et des plaquettes sanguines |
-
1971
- 1971-01-14 GB GB194071A patent/GB1356263A/en not_active Expired
-
1972
- 1972-01-10 CA CA132,060A patent/CA966830A/en not_active Expired
- 1972-01-11 ZA ZA720169A patent/ZA72169B/xx unknown
- 1972-01-12 NL NL7200481A patent/NL7200481A/xx not_active Application Discontinuation
- 1972-01-12 AT AT22572A patent/AT340604B/de not_active IP Right Cessation
- 1972-01-12 FR FR7200892A patent/FR2121772B1/fr not_active Expired
- 1972-01-13 SE SE7200373A patent/SE386450B/xx unknown
- 1972-01-13 DE DE19722201513 patent/DE2201513A1/de active Pending
- 1972-01-13 CH CH45772A patent/CH568760A5/xx not_active IP Right Cessation
- 1972-01-14 BE BE778102A patent/BE778102A/xx unknown
- 1972-01-14 AU AU37964/72A patent/AU3796472A/en not_active Expired
- 1972-01-14 IE IE53/72A patent/IE35980B1/xx unknown
- 1972-01-14 DK DK20072AA patent/DK129709B/da unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK129709C (enExample) | 1975-04-21 |
| DK129709B (da) | 1974-11-11 |
| CH568760A5 (enExample) | 1975-11-14 |
| ZA72169B (en) | 1972-09-27 |
| BE778102A (fr) | 1972-07-14 |
| IE35980L (en) | 1972-07-14 |
| FR2121772A1 (enExample) | 1972-08-25 |
| FR2121772B1 (enExample) | 1975-08-01 |
| NL7200481A (enExample) | 1972-07-18 |
| GB1356263A (en) | 1974-06-12 |
| CA966830A (en) | 1975-04-29 |
| ATA22572A (de) | 1977-04-15 |
| IE35980B1 (en) | 1976-07-21 |
| AT340604B (de) | 1977-12-27 |
| AU3796472A (en) | 1973-07-19 |
| SE386450B (sv) | 1976-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69621528T2 (de) | Anti-inflamatorische agenzien | |
| DE69622466T2 (de) | Inaktivierung von Prionen in Bindegewebematerialen | |
| DE3019350C2 (enExample) | ||
| DE69103755T2 (de) | Wachstumshormonkristalle und verfahren zu deren herstellung. | |
| DD157561A5 (de) | Verfahren zur herstellung von mucopolysacchariden | |
| EP0430200A1 (de) | Arzneimittel zur subkutanen oder intramuskulären Applikation enthaltend Polypeptide | |
| DE3337443A1 (de) | Den ph-wert regulierende materialien und ihre herstellung | |
| DE19614823A1 (de) | Ophthalmische Zusammensetzung mit verlängerter Verweilzeit am Auge | |
| CH685099A5 (de) | Pharmazeutisches Präparat für die intranasale Anwendung. | |
| DE69109886T2 (de) | Verfahren zur Herstellung von humanem Faktor VIII und dessen Analogen. | |
| DE10053053A1 (de) | Pharmazeutische Formulierungen zur Hemmung von entzündlichen Arthritiden | |
| DE69217338T2 (de) | Carboxyvinylpolymer mit newtonischer Viskosität | |
| EP0856312A1 (de) | Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten | |
| DE2461439B2 (de) | Verfahren zur Herstellung eines schützenden Antigens von BordeteUa Pertussis sowie jenes enthaltendes Mittel | |
| WO2003011340A1 (de) | Arzneiformulierung zur topischen anwendung für die therapie und prophylaxe von hyperhidrosis | |
| EP4392042A1 (de) | Injektionsbehälter, befüllt mit einer wasserhaltigen, injizierbaren zusammensetzung | |
| EP0493662B1 (de) | Verwendung von Superoxiddismutasen für die Herstellung von Arzneimitteln zur Prophylaxe und/oder Behandlung von Organversagen bei Risikopatienten mit Polytrauma als Unfallfolge | |
| DE69005251T2 (de) | Sulfatierte Glykosaminoglykuronane mit antithrombotischer Wirkung. | |
| DE2201513A1 (de) | Neue Modifikation natuerlicher doppelstrangiger Ribonucleinsaeuren mit antiviraler Aktivitaet und verminderter akuter toxischer Wirkung,Verfahren zu ihrer Herstellung sowie eine solche Modifikation enthaltende Arzneipraeparate | |
| DE60002448T2 (de) | Antibakterielle wässerige ophtalmische Formulierungen mit Ofloxacin und Chitosan | |
| WO2001051525A1 (de) | Heparin mit mittlerer molmasse | |
| DE1620629C3 (de) | Verwendung eines Salzes von 2-Merkaptoäthansulf onsäure zur Herstellung von Mukolytica | |
| DE69528890T2 (de) | Verwendung von substituierten dextranen zur behandlung von schädigungen des nervensystems, und fraktionen mit erhöhtem heparansulfat-gehalt | |
| DE1617659C3 (de) | Interferonbildendes Arzneimittel und dessen Verwendung | |
| DE60000658T2 (de) | Zusammensetzung zur behandlung von psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHA | Expiration of time for request for examination |